680 related articles for article (PubMed ID: 33213161)
1. Current treatment options for hepatocellular carcinoma.
Eugen K
Klin Onkol; 2020; 33(Supplementum 3):20-25. PubMed ID: 33213161
[TBL] [Abstract][Full Text] [Related]
2. Systemic targeted and immunotherapy for advanced hepatocellular carcinoma.
Cersosimo RJ
Am J Health Syst Pharm; 2021 Jan; 78(3):187-202. PubMed ID: 33211092
[TBL] [Abstract][Full Text] [Related]
3. Targeted and immune therapies for hepatocellular carcinoma: Predictions for 2019 and beyond.
Kudo M
World J Gastroenterol; 2019 Feb; 25(7):789-807. PubMed ID: 30809080
[TBL] [Abstract][Full Text] [Related]
4. Comparative Efficacy of Cabozantinib and Regorafenib for Advanced Hepatocellular Carcinoma.
Kelley RK; Mollon P; Blanc JF; Daniele B; Yau T; Cheng AL; Valcheva V; Marteau F; Guerra I; Abou-Alfa GK
Adv Ther; 2020 Jun; 37(6):2678-2695. PubMed ID: 32424805
[TBL] [Abstract][Full Text] [Related]
5. [Multimodal treatment of hepatocellular carcinoma].
Kirstein MM; Wirth TC
Internist (Berl); 2020 Feb; 61(2):164-169. PubMed ID: 31919533
[TBL] [Abstract][Full Text] [Related]
6. The New Era of Systemic Treatment for Hepatocellular Carcinoma: From the First Line to the Optimal Sequence.
Cerreto M; Cardone F; Cerrito L; Stella L; Santopaolo F; Pallozzi M; Gasbarrini A; Ponziani FR
Curr Oncol; 2023 Sep; 30(10):8774-8792. PubMed ID: 37887533
[TBL] [Abstract][Full Text] [Related]
7. Review article: new therapeutic interventions for advanced hepatocellular carcinoma.
Bangaru S; Marrero JA; Singal AG
Aliment Pharmacol Ther; 2020 Jan; 51(1):78-89. PubMed ID: 31747082
[TBL] [Abstract][Full Text] [Related]
8. Role of immunotherapy in the management of hepatocellular carcinoma: current standards and future directions.
Weinmann A; Galle PR
Curr Oncol; 2020 Nov; 27(Suppl 3):S152-S164. PubMed ID: 33343209
[TBL] [Abstract][Full Text] [Related]
9. First-Line Targeted Therapy for Hepatocellular Carcinoma: Role of Atezolizumab/Bevacizumab Combination.
Tella SH; Kommalapati A; Mahipal A; Jin Z
Biomedicines; 2022 Jun; 10(6):. PubMed ID: 35740326
[TBL] [Abstract][Full Text] [Related]
10. Emerging agents and regimens for hepatocellular carcinoma.
Zhu XD; Sun HC
J Hematol Oncol; 2019 Oct; 12(1):110. PubMed ID: 31655607
[TBL] [Abstract][Full Text] [Related]
11. Microvascular Invasion as a Predictor of Response to Treatment with Sorafenib and Transarterial Chemoembolization for Recurrent Intermediate-Stage Hepatocellular Carcinoma.
Peng Z; Chen S; Xiao H; Wang Y; Li J; Mei J; Chen Z; Zhou Q; Feng S; Chen M; Qian G; Peng S; Kuang M
Radiology; 2019 Jul; 292(1):237-247. PubMed ID: 31135299
[TBL] [Abstract][Full Text] [Related]
12. Systemic therapies for hepatocellular carcinoma: the present and the future.
Celsa C; Giuffrida P; Stornello C; Grova M; Spatola F; Rizzo GEM; Busacca A; Cannella R; Battaglia S; Cammà C; Cabibbo G
Recenti Prog Med; 2021 Feb; 112(2):110-116. PubMed ID: 33624623
[TBL] [Abstract][Full Text] [Related]
13. Transarterial Radioembolization Versus Atezolizumab-Bevacizumab in Unresectable Hepatocellular Carcinoma: A Matching-Adjusted Indirect Comparison of Time to Deterioration in Quality of Life.
Agirrezabal I; Brennan VK; Colaone F; Shergill S; Pereira H; Chatellier G; Vilgrain V
Adv Ther; 2022 May; 39(5):2035-2051. PubMed ID: 35279814
[TBL] [Abstract][Full Text] [Related]
14. Strategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma.
Xing R; Gao J; Cui Q; Wang Q
Front Immunol; 2021; 12():783236. PubMed ID: 34899747
[TBL] [Abstract][Full Text] [Related]
15. Systemic Treatment for Advanced Hepatocellular Carcinoma.
Bouattour M; Mehta N; He AR; Cohen EI; Nault JC
Liver Cancer; 2019 Oct; 8(5):341-358. PubMed ID: 31768344
[TBL] [Abstract][Full Text] [Related]
16. Navigating the new landscape of second-line treatment in advanced hepatocellular carcinoma.
Rimassa L; Wörns MA
Liver Int; 2020 Aug; 40(8):1800-1811. PubMed ID: 32432830
[TBL] [Abstract][Full Text] [Related]
17. Argentinian clinical practice guideline for surveillance, diagnosis, staging and treatment of hepatocellular carcinoma.
Piñero F; Tanno M; Aballay Soteras G; Tisi Baña M; Dirchwolf M; Fassio E; Ruf A; Mengarelli S; Borzi S; Fernández N; Ridruejo E; Descalzi V; Anders M; Mazzolini G; Reggiardo V; Marciano S; Perazzo F; Spina JC; McCormack L; Maraschio M; Lagues C; Gadano A; Villamil F; Silva M; Cairo F; Ameigeiras B;
Ann Hepatol; 2020; 19(5):546-569. PubMed ID: 32593747
[TBL] [Abstract][Full Text] [Related]
18. Recent Advances in Systemic Therapy for Hepatocellular Carcinoma in an Aging Society: 2020 Update.
Kudo M
Liver Cancer; 2020 Dec; 9(6):640-662. PubMed ID: 33442538
[TBL] [Abstract][Full Text] [Related]
19. Sequential therapies after atezolizumab plus bevacizumab or lenvatinib first-line treatments in hepatocellular carcinoma patients.
Persano M; Rimini M; Tada T; Suda G; Shimose S; Kudo M; Cheon J; Finkelmeier F; Lim HY; Presa J; Masi G; Yoo C; Lonardi S; Tovoli F; Kumada T; Sakamoto N; Iwamoto H; Aoki T; Chon HJ; Himmelsbach V; Niizeki T; Montes M; Vivaldi C; Soldà C; Stefanini B; Hiraoka A; Sho T; Nishida N; Steup C; Iavarone M; Di Costanzo G; Marra F; Tamburini E; Cabibbo G; Foschi FG; Silletta M; Hirooka M; Kariyama K; Tani J; Atsukawa M; Takaguchi K; Itobayashi E; Fukunishi S; Tsuji K; Ishikawa T; Tajiri K; Ochi H; Yasuda S; Toyoda H; Ogawa C; Nishimura T; Hatanaka T; Kakizaki S; Shimada N; Kawata K; Tada F; Ohama H; Nouso K; Morishita A; Tsutsui A; Nagano T; Itokawa N; Okubo T; Arai T; Imai M; Kosaka H; Naganuma A; Koizumi Y; Nakamura S; Kaibori M; Iijima H; Hiasa Y; Campani C; Amadeo E; Rossari F; Burgio V; Cascinu S; Scartozzi M; Casadei-Gardini A
Eur J Cancer; 2023 Aug; 189():112933. PubMed ID: 37385069
[TBL] [Abstract][Full Text] [Related]
20. [New Systemic Therapies for Advanced Hepatocellular Carcinoma].
Kim DY
Korean J Gastroenterol; 2019 Jan; 73(1):10-15. PubMed ID: 30690953
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]